1. Home
  2. JNJ
  3. JNJ News

Latest Johnson & Johnson (JNJ) News on November 20, 2025

Knee Replacement Surgery Market Analysis Report 2025-2035: Stryker, Zimmer Biomet, B. Braun, and DePuy Synthes Lead Innovations by Continually Innovating and Improving Patient Outcomes
JNJ

GlobeNewswire

17 hours ago

Knee Replacement Surgery Market Analysis Report 2025-2035: Stryker, Zimmer Biomet, B. Braun, and DePuy Synthes Lead Innovations by Continually Innovating and Improving Patient Outcomes

Why Johnson & Johnson (JNJ) Is Up 5.9% After Multiple FDA Approvals and Positive Drug Trial Results
JNJ

Simply Wall St.

a day ago

Why Johnson & Johnson (JNJ) Is Up 5.9% After Multiple FDA Approvals and Positive Drug Trial Results

J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B
JNJ

Zacks

2 days ago

J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B

Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3
JNJ

Zacks

2 days ago

Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3

Johnson & Johnson Buys Prostate Cancer Treatment-Maker Halda for $3.1 Billion
JNJ

The Daily Upside

2 days ago

Johnson & Johnson Buys Prostate Cancer Treatment-Maker Halda for $3.1 Billion

Johnson & Johnson to acquire Halda Therapeutics for $3.05bn
JNJ

Pharmaceutical Technology

2 days ago

Johnson & Johnson to acquire Halda Therapeutics for $3.05bn

The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum
JNJ

Zacks

2 days ago

The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum

Johnson & Johnson Expands Oncology Pipeline with $3.05 Billion Halda Acquisition
JNJ

GuruFocus.com

2 days ago

Johnson & Johnson Expands Oncology Pipeline with $3.05 Billion Halda Acquisition

Stock Market Today: Dow Skids, AI Play Dives As Peter Thiel Exits; Netflix Divvies Up Its Shares (Live Coverage)
JNJ

Investor's Business Daily

2 days ago

Stock Market Today: Dow Skids, AI Play Dives As Peter Thiel Exits; Netflix Divvies Up Its Shares (Live Coverage)

JNJ

MT Newswires

2 days ago

Sector Update: Health Care Stocks Softer Late Afternoon

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion
JNJ

Barrons.com

3 days ago

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion

JNJ

MT Newswires

3 days ago

Sector Update: Health Care

Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment
JNJ

Investor's Business Daily

3 days ago

Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment

JNJ

MT Newswires

3 days ago

Johnson & Johnson to Buy Halda Therapeutics for $3.05 Billion in Cash

Halda Therapeutics Announces Acquisition by Johnson & Johnson
JNJ

GlobeNewswire

3 days ago

Halda Therapeutics Announces Acquisition by Johnson & Johnson

New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
JNJ

PR Newswire

3 days ago

New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis

Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics
JNJ

Business Wire

3 days ago

Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics

Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJ
JNJ

Zacks

3 days ago

Growth or Stability? A 2025 Investment Face-Off Between LLY and JNJ

Johnson & Johnson (JNJ) Emerges as Scotiabank’s Top Pick for Curative Treatments
JNJ

Insider Monkey

4 days ago

Johnson & Johnson (JNJ) Emerges as Scotiabank’s Top Pick for Curative Treatments

Bristol Myers Slouches 4% After Experts Say Its Heart Drug Will Fail
JNJ

Investor's Business Daily

5 days ago

Bristol Myers Slouches 4% After Experts Say Its Heart Drug Will Fail

JNJ

MT Newswires

5 days ago

Sector Update: Health Care Stocks Ease Late Afternoon

JNJ

MT Newswires

5 days ago

US Equity Indexes Mixed Amid Technology Rebound

JNJ

MT Newswires

6 days ago

Sector Update: Health Care Stocks Fall Friday Afternoon

JNJ

MT Newswires

6 days ago

US Equity Indexes Mixed as Technology Rebound Helps Lift Nasdaq, S&P 500

How Recent Moves Are Rewriting the Story for Pfizer
JNJ

Simply Wall St.

6 days ago

How Recent Moves Are Rewriting the Story for Pfizer

JNJ

MT Newswires

6 days ago

Sector Update: Health Care

Bristol Myers Shares Sink on Yet Another Trial Failure
JNJ

Barrons.com

6 days ago

Bristol Myers Shares Sink on Yet Another Trial Failure

JNJ

MT Newswires

6 days ago

Market Chatter: Judge to Decide on Texas AG's Bid to Block Kenvue's Dividend

Bristol Myers Slumps After Its Heart Condition Study Gets The Boot
JNJ

Investor's Business Daily

6 days ago

Bristol Myers Slumps After Its Heart Condition Study Gets The Boot

JNJ

MT Newswires

6 days ago

Sector Update: Health Care Stocks Decline Premarket Friday

JNJ

MT Newswires

6 days ago

Sector Update: Health Care

Pharma ETFs in Spotlight Following Robust Q3 Earnings Results
JNJ

Zacks

6 days ago

Pharma ETFs in Spotlight Following Robust Q3 Earnings Results

Update on Phase 3 Librexia ACS Trial
JNJ

Business Wire

6 days ago

Update on Phase 3 Librexia ACS Trial

Jim Cramer Shows Confidence in Amgen
JNJ

Insider Monkey

7 days ago

Jim Cramer Shows Confidence in Amgen

Jim Cramer Notes Johnson & Johnson is “Really Bearing Down on High-Growth Pharma”
JNJ

Insider Monkey

7 days ago

Jim Cramer Notes Johnson & Johnson is “Really Bearing Down on High-Growth Pharma”

Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls
JNJ

The Fly

7 days ago

Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month
JNJ

Zacks

7 days ago

Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month

JNJ

MT Newswires

7 days ago

Scotiabank Initiates Johnson & Johnson at Sector Outperform With $230 Price Target

2 Healthcare Stocks for Beginner Investors With a 40-Year Time Horizon
JNJ

Motley Fool

7 days ago

2 Healthcare Stocks for Beginner Investors With a 40-Year Time Horizon

2 Strong Healthcare Stock Picks for Dividend Investors
JNJ

Motley Fool

7 days ago

2 Strong Healthcare Stock Picks for Dividend Investors

BeOne, IBD Stock Of The Day, Breaks Out As It Takes On Cancer Giants J&J, AbbVie
JNJ

Investor's Business Daily

7 days ago

BeOne, IBD Stock Of The Day, Breaks Out As It Takes On Cancer Giants J&J, AbbVie

Walt Disney and 15 More Non-AI Stocks Worth a Look
JNJ

Barrons.com

7 days ago

Walt Disney and 15 More Non-AI Stocks Worth a Look

Bayer Q3 Earnings Beat Estimates on Crop Science Business Gains
JNJ

Zacks

8 days ago

Bayer Q3 Earnings Beat Estimates on Crop Science Business Gains

J&J's MedTech Unit Sales Improve: Will the Momentum Last?
JNJ

Zacks

8 days ago

J&J's MedTech Unit Sales Improve: Will the Momentum Last?

Assessing Johnson & Johnson's Value After Medtech Acquisition and 34.6% Year-to-Date Surge
JNJ

Simply Wall St.

8 days ago

Assessing Johnson & Johnson's Value After Medtech Acquisition and 34.6% Year-to-Date Surge

Lantheus, Enovis, Evolent Health, Repligen, and Corcept Shares Are Soaring, What You Need To Know
JNJ

StockStory

8 days ago

Lantheus, Enovis, Evolent Health, Repligen, and Corcept Shares Are Soaring, What You Need To Know

Merck, Elanco, Myriad Genetics, Neogen, and Cigna Shares Are Soaring, What You Need To Know
JNJ

StockStory

8 days ago

Merck, Elanco, Myriad Genetics, Neogen, and Cigna Shares Are Soaring, What You Need To Know

Gilead Sciences, Moderna, Artivion, Tenet Healthcare, and Charles River Laboratories Stocks Trade Up, What You Need To Know
JNJ

StockStory

8 days ago

Gilead Sciences, Moderna, Artivion, Tenet Healthcare, and Charles River Laboratories Stocks Trade Up, What You Need To Know

Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know
JNJ

StockStory

8 days ago

Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know

Elevance Health, Labcorp, Privia Health, Fortrea, and Amgen Shares Are Soaring, What You Need To Know
JNJ

StockStory

8 days ago

Elevance Health, Labcorp, Privia Health, Fortrea, and Amgen Shares Are Soaring, What You Need To Know

Bio-Techne, Tandem Diabetes, Align Technology, DexCom, and Teleflex Shares Skyrocket, What You Need To Know
JNJ

StockStory

8 days ago

Bio-Techne, Tandem Diabetes, Align Technology, DexCom, and Teleflex Shares Skyrocket, What You Need To Know

Pulmonary Arterial Hypertension Market Research Report 2025, Competitive Analysis of Gilead Sciences, Viatris, Sandoz, J&J, Sun Pharma, Lupin Pharma, GlaxoSmithKline, Bayer, United Therapeutics
JNJ

GlobeNewswire

9 days ago

Pulmonary Arterial Hypertension Market Research Report 2025, Competitive Analysis of Gilead Sciences, Viatris, Sandoz, J&J, Sun Pharma, Lupin Pharma, GlaxoSmithKline, Bayer, United Therapeutics

Black Hair Accessories Brand Targets $50M Revenue By 2030 With New Products, Market Expansion
JNJ

Black Enterprise

10 days ago

Black Hair Accessories Brand Targets $50M Revenue By 2030 With New Products, Market Expansion

Jim Cramer Says Haleon’s “Stock’s Been Struggling”
JNJ

Insider Monkey

11 days ago

Jim Cramer Says Haleon’s “Stock’s Been Struggling”

Jim Cramer Says He “Believed in” Bristol-Myers’ Cobenfy But “It’s Not Selling Well at All”
JNJ

Insider Monkey

12 days ago

Jim Cramer Says He “Believed in” Bristol-Myers’ Cobenfy But “It’s Not Selling Well at All”

Will Recursion Pharmaceuticals’ (RXRX) New CEO Accelerate Its AI Ambitions and Strategic Partnerships?
JNJ

Simply Wall St.

13 days ago

Will Recursion Pharmaceuticals’ (RXRX) New CEO Accelerate Its AI Ambitions and Strategic Partnerships?

J&J’s Darzalex gains first FDA approval in smouldering multiple myeloma
JNJ

Pharmaceutical Technology

13 days ago

J&J’s Darzalex gains first FDA approval in smouldering multiple myeloma

Is a Market Correction Coming? Better Grab 5 of the Safest Dividend Kings Now
JNJ

24/7 Wall St.

13 days ago

Is a Market Correction Coming? Better Grab 5 of the Safest Dividend Kings Now

FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma
JNJ

PR Newswire

13 days ago

FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
JNJ

PR Newswire

13 days ago

DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma

How Recent Developments Are Shaping the Johnson & Johnson Investment Story
JNJ

Simply Wall St.

13 days ago

How Recent Developments Are Shaping the Johnson & Johnson Investment Story

J&J’s Caplyta wins MDD approval to extend revenue horizon
JNJ

Pharmaceutical Technology

14 days ago

J&J’s Caplyta wins MDD approval to extend revenue horizon

JNJ

MT Newswires

14 days ago

Texas Attorney General Files Motion to Stop Kenvue From Paying November Dividends

Chronic Heart Failure Market Analysis and Forecast, 2025-2035, Featuring AstraZeneca, Bristol Myers Squibb, Cytokinetics, Bayer, Eli Lilly and Other Leading Players
JNJ

GlobeNewswire

14 days ago

Chronic Heart Failure Market Analysis and Forecast, 2025-2035, Featuring AstraZeneca, Bristol Myers Squibb, Cytokinetics, Bayer, Eli Lilly and Other Leading Players

AstraZeneca CEO bullish on record revenue numbers and US growth
JNJ

Yahoo Finance Video

14 days ago

AstraZeneca CEO bullish on record revenue numbers and US growth

FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
JNJ

PR Newswire

14 days ago

FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder

Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe
JNJ

Business Wire

14 days ago

Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe

Johnson & Johnson to Participate in the Citi’s 2025 Global Healthcare Conference
JNJ

Business Wire

14 days ago

Johnson & Johnson to Participate in the Citi’s 2025 Global Healthcare Conference

JNJ

Morningstar Research

14 days ago

Analyst Report: Royalty Pharma plc

This Healthcare Stock Is the Worst Performer in the S&P 500 Today. Here’s Why.
JNJ

Barrons.com

14 days ago

This Healthcare Stock Is the Worst Performer in the S&P 500 Today. Here’s Why.

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
JNJ

Zacks

15 days ago

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Jim Cramer Just Couldn’t Help Himself When Talking About Kimberly-Clark (KMB)’s Kenvue Acquisition
JNJ

Insider Monkey

15 days ago

Jim Cramer Just Couldn’t Help Himself When Talking About Kimberly-Clark (KMB)’s Kenvue Acquisition

Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View
JNJ

Zacks

16 days ago

Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View

Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn
JNJ

Pharmaceutical Technology

16 days ago

Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn

$144.85 Bn Disposable Medical Device Markets, 2025-2030: Opportunities in Innovation in Sustainable Materials, and Expansion in Emerging Markets and Underserved Regions
JNJ

GlobeNewswire

16 days ago

$144.85 Bn Disposable Medical Device Markets, 2025-2030: Opportunities in Innovation in Sustainable Materials, and Expansion in Emerging Markets and Underserved Regions

Kimberly-Clark Takeover Offers $48 Billion of Pain Relief to Tylenol-Maker Kenvue
JNJ

The Daily Upside

16 days ago

Kimberly-Clark Takeover Offers $48 Billion of Pain Relief to Tylenol-Maker Kenvue

Kimberly-Clark To Acquire Kenvue In $48.7 Billion Mega Deal
JNJ

GuruFocus.com

16 days ago

Kimberly-Clark To Acquire Kenvue In $48.7 Billion Mega Deal

Will Pipeline Milestones and New Oral Therapies Shift Johnson & Johnson's (JNJ) Growth Narrative?
JNJ

Simply Wall St.

16 days ago

Will Pipeline Milestones and New Oral Therapies Shift Johnson & Johnson's (JNJ) Growth Narrative?

Alvotech faces FDA setback for its Simponi biosimilar AVT05
JNJ

Pharmaceutical Technology

16 days ago

Alvotech faces FDA setback for its Simponi biosimilar AVT05

Tulyp Medical Emerges From Sofinnova’s Medtech Accelerator and Announces FDA Submission Following Initial First-in-Human Use
JNJ

Business Wire

16 days ago

Tulyp Medical Emerges From Sofinnova’s Medtech Accelerator and Announces FDA Submission Following Initial First-in-Human Use

JNJ

Morningstar Research

16 days ago

Analyst Report: Kenvue Inc.

Kimberly-Clark Stock Takes Biggest One-Day Hit Since Black Monday
JNJ

The Wall Street Journal

16 days ago

Kimberly-Clark Stock Takes Biggest One-Day Hit Since Black Monday

Kimberly-Clark to Buy Tylenol Maker Kenvue. Why Kimberly-Clark Stock Is Tanking.
JNJ

Barrons.com

17 days ago

Kimberly-Clark to Buy Tylenol Maker Kenvue. Why Kimberly-Clark Stock Is Tanking.

Kimberly-Clark to buy Kenvue, maker of Tylenol, in $48 billion deal
JNJ

USA TODAY

17 days ago

Kimberly-Clark to buy Kenvue, maker of Tylenol, in $48 billion deal

Kimberly-Clark buys Tylenol maker Kenvue for more than $48 billion
JNJ

Quartz

17 days ago

Kimberly-Clark buys Tylenol maker Kenvue for more than $48 billion

Kimberly-Clark Strikes $40 Billion Deal for Tylenol Maker Kenvue
JNJ

The Wall Street Journal

17 days ago

Kimberly-Clark Strikes $40 Billion Deal for Tylenol Maker Kenvue

Tylenol, Kleenex, Band-Aid and more put under one roof in $48.7 billion consumer brands deal
JNJ

Associated Press Finance

17 days ago

Tylenol, Kleenex, Band-Aid and more put under one roof in $48.7 billion consumer brands deal

Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
JNJ

GlobeNewswire

17 days ago

Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors

Kimberly-Clark to Acquire Kenvue
JNJ

WWD

17 days ago

Kimberly-Clark to Acquire Kenvue

Japan Non-Invasive Aesthetic Treatment Market Analysis and Outlook 2025-2033 with City-Level Breakdowns by Procedure, Gender and End User
JNJ

GlobeNewswire

17 days ago

Japan Non-Invasive Aesthetic Treatment Market Analysis and Outlook 2025-2033 with City-Level Breakdowns by Procedure, Gender and End User

AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised
JNJ

Zacks

20 days ago

AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised

Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings?
JNJ

Zacks

20 days ago

Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings?

Appointment of Yves Decadt as Member of Poxel’s Board of Directors
JNJ

Business Wire

20 days ago

Appointment of Yves Decadt as Member of Poxel’s Board of Directors

I’m 65, itching to retire but only have $500K saved. I want $2K/month plus my Social Security — how can I swing this?
JNJ

Moneywise

20 days ago

I’m 65, itching to retire but only have $500K saved. I want $2K/month plus my Social Security — how can I swing this?

AbbVie Beats Third-Quarter Estimates. There’s More to the Drugmaker’s Earnings.
JNJ

Barrons.com

20 days ago

AbbVie Beats Third-Quarter Estimates. There’s More to the Drugmaker’s Earnings.

JNJ

MT Newswires

20 days ago

Nanobiotix to Receive Up to $71 Million in Royalty Financing From HealthCare Royalty

The Zacks Analyst Blog Highlights Broadcom, Johnson & Johnson, Palantir Technologies, Fossil Group and Moving iMage
JNJ

Zacks

20 days ago

The Zacks Analyst Blog Highlights Broadcom, Johnson & Johnson, Palantir Technologies, Fossil Group and Moving iMage

Top Analyst Reports for Broadcom, Johnson & Johnson and Palantir
JNJ

Zacks

20 days ago

Top Analyst Reports for Broadcom, Johnson & Johnson and Palantir

Bladder Cancer Market - Global and Regional Analysis and Forecast (2025-2035) Featuring Merck & Co., Bristol Myers Squibb, Astellas Pharma, AstraZeneca, and Johnson & Johnson
JNJ

GlobeNewswire

21 days ago

Bladder Cancer Market - Global and Regional Analysis and Forecast (2025-2035) Featuring Merck & Co., Bristol Myers Squibb, Astellas Pharma, AstraZeneca, and Johnson & Johnson

Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock
JNJ

Zacks

21 days ago

Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock

Share on Social Networks: